Advances in the Treatment of Acute Myeloid Leukemia: EHA 2002
This year at the 7th Congress of the European Hematological Association (EHA), the agent that received the most attention for the treatment of AML was Mylotarg®.

Multiple Myeloma: A Treatment Update: EHA 2002
This meeting had several interesting papers on the use of thalidomide for myeloma and the continued investigation of autologous and allogeneic stem cell transplantation.

Overview of the Treatment of Hodgkin's and Non-Hodgkin's Lymphomas: EHA 2002
French researchers reported that involved-field radiation was of no benefit for patients with stage III-IV Hodgkin’s lymphoma that achieved a CR following chemotherapy. 1 However, involved-field radiation was of benefit for those who achieved only a PR.

Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphoid Leukemia and Chronic Myeloid Leukemia
At the 7th Congress of the European Hematology Association, there were no new developments in the conventional treatment for ALL that had not been presented at the American Society of Hematology meeting in December of 2001 or the American Society of Clinical Oncology meeting in May of 2002.